Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARDINALS phase 2 trial of utreloxastat in adults with amyotrophic lateral sclerosis
jRCT2011230043Phase 2Completed
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Oct 2023
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing utreloxastat with placebo (2 arms). Primary endpoint: Change from baseline in ALS Functional Rating Scale-Revised. Started Oct 2023; status: completed.
02
Drugs
utreloxastat
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on jRCT2011230043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011230043.